Board of Directors

Doughtie previously served as Vice Chair of KPMG’s Advisory business (2011-2015), establishing it as the firm’s fastest-growing business. In addition, she oversaw the expansion of KPMG’s capabilities in innovative services and solutions, including information security, strategy, digital/mobile, and transformation.

Doughtie began her career in 1985 in KPMG’s Audit practice, and served in a number of national, regional and global leadership roles, including as lead partner for a number of the firm’s major clients.

He joined IBM in January 2023 from Lazard, where he served as President since June 2019. Prior to that, Alex held a number of senior executive positions at the firm, including Chief Executive Officer of Lazard’s Financial Advisory business, Chief Operating Officer, and Global Head of Strategy.

Alex spearheaded many of the firm’s key strategic and operational initiatives, including expanding Lazard’s service offerings, enhancing collaboration and productivity across the firm’s workforce, and strengthening relationships with investment banking clients. He also helped lead the successful integration of Lazard as it transitioned from a private partnership to a public company. Throughout his tenure, Alex advised Lazard clients on a broad array of transformational growth transactions and value creation initiatives, with a particular emphasis in the technology and telecommunications sectors. He joined Lazard in 1994, and was named Managing Director in 2002.

Alex previously held positions with Patricof & Co. Ventures and IBM. He serves on the Board of Advisors for the School of Engineering and Applied Science of the University of Pennsylvania and is a board member of the nonprofit Operation Warm.

He received a BS from Duke University, an MSE from the School of Engineering and Applied Science of the University of Pennsylvania, and an MBA from The Wharton School of the University of Pennsylvania.
 

After two surgeries, including the removal of her left lobe and lymph nodes, she has been cancer-free since 2017.  Nichelle has made it her fight to educate, facilitate, engage, and organize those in powerful positions to bring about change in the pursuit of equity for all.

Nichelle is an educator in Oak Park, IL, and, in addition to her passion for equality in cancer care, is an advocate for equality in education. She believes that knowledge can be a place of enlightenment, and she teaches her kids to practice leading with love in all interactions. Nichelle lives in Oak Park, IL, with her young son Parker and husband Aaron.

Terri Ann is on the LUNGevity Early Lung Cancer Center’s External Advisory Board and spoke at its initial meeting. She actively promotes early detection through her speaking events and media platforms and shares how her experiences have profoundly changed her perspective and gratitude for every day.

Andrea came to LUNGevity through the merger with Protect Your Lungs, an organization she and her family started to fund lung cancer research following her mother’s death from lung cancer in 2008.

Before the merger, Andrea founded and built Protect Your Lungs, an organization dedicated to funding research into the early detection of lung cancer. Andrea was instrumental in building PYL’s Scientific Advisory Board and establishing its funding process, both of which followed her to the new LUNGevity organization.

In her for-profit career, Andrea has a wealth of management experience. Andrea was the Vice President of Strategy and Growth of Decision Lens, Inc. a company she helped launch in January 2005. Prior to joining Decision Lens, Andrea held a variety of management positions at Johnson & Johnson, including Director of Investor Relations, Manager Corporate Mergers & Acquisitions, and Plant Controller. She also spent several years at McNeil Consumer Products, a J&J subsidiary, in marketing and mergers & acquisitions. Prior to her time at J&J, Andrea worked for Lehman Brothers and Coopers & Lybrand in New York City in both Mergers and Acquisitions and as a CPA.

Andrea received her BS in Economics from Wharton with concentrations in Accounting, Decision Sciences, and Finance. She received her MBA from Wharton with concentrations in Finance and Latin American Studies. She served on Washington, DC’s Kennedy Center National Committee of Performing Arts and on the Board of ARCS (Achievement Rewards for College Scientists) of Metro DC. She has also served on the Executive Committee of the Board of Directors for DC Metro Boys and Girls Club and has worked with the Ronald McDonald House and the Philadelphia Museum of Art.

BJ brings 30 years of commercial and launch experience in the US and globally, with particular experience in driving mass-market product launch strategies for industry-leading brands. BJ was previously CCO, Migraine and Common Disease, at Biohaven Pharmaceuticals, and held leadership roles of increasing responsibility at Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, and NitroMed. He has successfully built and led diverse commercial teams committed to addressing unmet patient needs across various therapeutic areas, including neuroscience, cardio-metabolic, respiratory, GI, and infectious disease.

Prior to joining the pharmaceutical industry, BJ served in the US Air Force and earned the rank of Major. He provided threat assessments to NATO leadership as an engineering analyst in the Foreign Technology division and led cutting-edge research in the Artificial Intelligence in Training program as a function chief in the AF Human Systems Division.

He holds a BS in Human Factors Engineering from the US Air Force Academy, an MS in Industrial Engineering from Texas A&M University, and an MBA from Stanford Graduate School of Business.

 

In particular, Jennifer assists companies in developing comprehensive global and domestic privacy and data security programs, guiding companies in navigating the myriad state, federal, and international privacy regulations. Jennifer also devotes a significant portion of her practice to incident response and preparation, having advised numerous companies on the implementation of an incident response program and coaching companies through evaluating and responding to a threatened or actual security incident. Further, Jennifer routinely advises clients on privacy and data security matters in the context of corporate transactions, working with clients to identify potential risks in an acquisition, whether buy or sell side.

Dr. Kolodziej attended college and medical school at Washington University in St. Louis, where he was Phi Beta Kappa and Alpha Omega Alpha. He completed his internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia.  Thereafter Dr. Kolodziej joined the faculty at the University of Oklahoma School of Medicine as an associate professor. In the winter of 1998, he joined New York Oncology and was a partner in the practice until December 2012.

Dr. Kolodziej was an active member of the US Oncology Pharmacy and Therapeutics committee, serving on the executive committee from 2002-2011, and as chairman from 2004-2011. He also served as Medical Director for Oncology Services for US Oncology (USON) from 2007-2011. In this role, Dr. Kolodziej helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology.

Dr. Kolodziej joined Aetna in January 2013 as National Medical Director, Oncology Solutions. While at Aetna, he directed its oncology delivery reform pilots and was the architect of the Aetna Oncology Medical Home program. He was also active in Aetna’s pharmacy policy, condition analysis, and genetics subcommittees.

Dr. Kolodziej joined Flatiron Health in July 2016 as National Medical Director, Managed Care Strategy, where he applied the core technology and data capabilities of Flatiron to facilitate practice transformation and success in alternative payment models. In 2017, he joined ADVI Health as Senior Advisor.

In executive operating roles across the personal care and health & wellness sectors, he has turned emerging businesses into top 5 brands, including Clean & Clear®, Listerine® and the OGX® hair care brand. Michael specializes in leading early-stage growth brands to highly profitable global market leadership by nurturing start-up cultures while scaling capabilities. His expertise: retail acceleration strategy, human performance, and consumer brand building through a mastery of the P&L.

Michael is the CEO of Raw Sugar, a national lifestyle brand that makes clean, premium, and healthy living products affordably. His key responsibilities include driving rapid growth by increasing brand love, expanding categories and geographical regions, and defining the next generation of an omni-channel, global consumer business.

Previously, Michael was the Global President of Vogue International where he drove the OGX® and Maui Moisture® Brands to YoY market share growth, global expansion, and operating margin improvement while scaling the business into iconic brands. He formerly held several executive roles at Johnson & Johnson, with the latest as President where he managed a $1.3B portfolio of brands.

A career highlight is securing the successful delivery of the $3.3B Vogue International acquisition by Johnson & Johnson, resulting in $1B+ increase in shareholder value and the retention of all top talent for the first 5 years of integration. Additional career milestones are managing the turnaround of the $1.3B portfolio of businesses. Michael is especially proud of his DE&I leadership, including leading the LGBTQIA+ “Care with Pride” retail initiative to double in funding and securing equity investment for Black-owned beauty start-ups as outcomes of ongoing ally work with underserved communities.

A visionary leader with an eye always on the next frontier, Michael has the work ethic of an athlete and the heart of a coach.

Michael holds a BSBA in Accounting and is a 3-time US Rowing All-American. He is an Executive Board member of the LUNGevity Foundation, a non-profit organization supporting lung cancer research. Born on the naval base in South Philly, he enjoys rowing in the morning and cycling with the guys. Lately, though, as a #GirlDad of two lovely daughters, he finds himself reveling alongside them in Broadway Shows and boy band concerts.

Barry is a committee member of the Partners in Clinical Research Conference and the Patient Advisory Council at Kyruus Health, and he co-creates projects for Patient-Centered Outcomes Research Initiatives (PCORI). He volunteers with Dana-Farber Cancer Institute as a community ambassador and on a community level in Boston to educate black men about lung cancer. Barry received a BS in business administration from Eastern Nazarene College.

He has stewarded the company’s rise to the worldwide leading provider of innovative venue services and live experiences. Bob has a personal family connection to cancer that motivates his advocacy and philanthropy. He received his BS in marketing from the University of Connecticut and an MS in sport management from the University of Massachusetts.

In the past, Andre served as a member of the Counseling and Regulatory Policy Group of the US Securities and Exchange Commission’s Office of General Counsel, where he provided advice and recommendations on various proposals presented for Commission action. He has also advised on policy issues as Counsel to SEC Commissioner Steven M. H. Wallman.

Andre graduated from Providence College with a bachelor’s degree and holds a JD degree from Harvard Law School.

He spent 17 years within the Ogilvy Healthcare organization, where he worked across all aspects of the oncology marketplace, creating long-standing partnerships with many biopharma companies and academic centers on the cutting edge of cancer research. He is a critical thinker, problem solver, and someone who thrives in new emerging approaches to solving the world’s biggest healthcare challenges.

Named to the PharmaVOICE 100 Most Inspiring Healthcare Leaders in 2016 for his leadership and innovation in cancer and rare diseases, Michael is a recognized leader and cancer advocate. He currently serves as the President of the Board of Trustees of CancerCare, a partner of LUNGevity. Additionally, since 2012 he has served on the board of the NCCN Foundation, an organization that represents 28 of the world’s leading cancer centers.

Michael holds a BA degree in psychology, which is where he became a hospice counselor, focused specifically on dealing with people suffering the end stage of a cancer diagnosis. He also holds an MBA in corporate finance.

In the war against lung cancer, Dr. Rudin is staging a strategic multi-pronged attack on the disease. A world-renowned researcher, Dr. Rudin conducts basic science research, develops cutting edge translational therapeutics, and treats lung cancer patients.

As Chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, Dr. Rudin utilizes his exceptional skills to effectively blend basic science and translational research. By using fresh tumor samples from the patient clinic across the street from his laboratory, Dr. Rudin’s team studies lung cancer and develops novel therapeutics in the lab. These techniques are then taken back to the clinic to be tested in patients who are participating in early stage clinical trials. It is a powerful cycle.

Already his laboratory has run numerous clinical trials looking at novel therapeutics in lung cancer patients. One of his exciting findings is a virus that targets small cell lung cancer. This groundbreaking work has prompted a national clinical trial to consider the possibility of using this virus to help specifically target and kill lung cancer cells. The blood and tumor samples from this trial are returning to Dr. Rudin’s laboratory so that his team can study the effects of the virus on lung cancer and conduct correlative analyses.

In this way, Dr. Rudin’s lab is creating real-time, parallel developments in the laboratory and the clinic that may be the foundation for major breakthroughs in lung cancer care.

While Dr. Rudin is working to develop therapeutics in the laboratory, he also treats patients on a regular basis. Dr. Rudin, a member of LUNGevity’s Scientific Advisory Board, knows that by the time lung cancer is detected, it’s usually too late. “To really have an impact, early detection is going to be essential,” says Dr. Rudin. “A recent national lung cancer screening trial showed that early detection is possible and it can have an impact on mortality rates, but it’s not enough…We need better, cheaper early detection techniques that can be used to screen all people.”

The development of detection techniques and therapeutics costs money. Sadly, there is a huge disparity between lung cancer research funding and research funding for other cancers, such as breast and prostate cancer, says Dr. Rudin. But that is where organizations like LUNGevity make a large impact. “Funding from LUNGevity really complements the federal funding system and helps to improve outcomes for lung cancer patients.”

Dr. Rudin’s complex, multi-pronged attack on lung cancer is based on a very simple idea – saving lives. “Every week I see patients with this disease. Every week patients suffer relapses. I have watched too many lung cancer patients die. I am trying to change the outcome for patients with this disease.”

Please find more information on Dr. Rudin here.

He attends the annual LUNGevity Scientific and Clinical Roundtable to represent the patient voice. Frank actively advocates for LUNGevity and the ALK+ lung cancer community and calls on industry, regulators, and fellow patients to challenge the status quo and explore what’s possible. He received a BSBA in accounting from Creighton University and an MBA from the University of Nebraska at Omaha.

At present, Andy is Co-Chief Executive Officer at Aurify Brands, a New York-based business catalyst focused on building and operating a portfolio of companies in a variety of industries, including finance, technology and multi-unit franchise concepts.

Prior to joining FPP, Andy founded AMT Partners, an investment group focused on personal private equity investments. Previously, Andy was a Managing Director and Entrepreneur-In-Residence of idealab!, where he managed portfolio company development, which included idea vetting, strategic planning and technical development. Andy joined idealab! upon the company’s acquisition of VenCatalyst, Inc., a company he founded and the East Coast’s first for-profit idea accelerator. Prior to starting VenCatalyst, Andy founded Logex International LLC, one of the first electronic commerce solutions providers. Logex was acquired by AppNet, Inc. (now CommerceOne), an e-commerce outsourcing conglomerate. After the acquisition, Andy joined AppNet’s senior management team as VP of Marketing, where he successfully guided the company through its initial public offering.

Andy serves on the board of Blue Point Ventures, LLC, FGNY, LLC and as Chairman of The Greenhouse, LLC.

Andy received his BA in Political Science from Vanderbilt University. He resides in Connecticut with his wife and three children.

Paul is determined to find an early detection strategy to find all lung cancers while they are still local and treatable to prevent lung-cancer related death. Paul is proud to now serve on LUNGevity’s Board of Directors.

Paul has been a leader in the business and non-profit community for more than four decades. He is the former Presiding Director of Dow Chemical Company and a former Director of Whirlpool Corporation.

Paul's not-for-profit activities include: Chairman, Washington National Symphony Orchestra; Board of Directors, Business Executives for National Security; Member of the Council on Foreign Relations; and member of the Potomac Officers Club; and Board member of the SEI Institute at the Wharton School of Business.

Paul lives in Potomac, MD, near three of his eight grandchildren.

Leading by example, Winn is nationally recognized for his community engagement efforts in promoting new approaches to building trust among populations previously disenfranchised from healthcare or excluded or abused in research. Winn is also the namesake of the Robert A. Winn Diversity in Clinical Trials Award Program, a $114 million training and education program in partnership with the Bristol Myers Squibb Foundation.

Winn is committed to both community-engaged research and research focused on eliminating health disparities. He is principal investigator on several large multi-institutional initiatives, including a team science award from Stand Up To Cancer, a National Cancer Institute (NCI)-funded Planning SPORE focused on Lung Cancer Health Equity and an NCI-funded institutional partnership award fostering cancer disparities research and career development collaboration between Massey and Virginia State University, a Historically Black University located in Petersburg, VA - a city that has faced health and education inequities for generations. Winn also manages his own basic and translational research laboratory which has been supported by multiple NIH and Veterans Affairs Merit awards for nearly two decades. Winn’s laboratory focuses on the molecular mechanisms and novel therapeutic approaches for lung cancer and the confluence between societal and biological factors which may lead to disparities.

The recipient of numerous awards and honors, Winn has received the National Cancer Institute Center to Reduce Cancer Health Disparities CURE Program Lifetime Achievement Award; the American Association for Cancer Research (AACR)-Minorities in Cancer Research Jane Cooke Wright Lectureship; the inaugural AACI Cancer Health Equity Award; and the Prevent Cancer Foundation Cancer Prevention and Early Detection Laurel Award for Increasing Health Equity. He is also a Fellow of the AACR Academy. Winn serves the President of the Association of American Cancer Institutes (AACI); Chair of the National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine; and a member of the Board of Directors for the American Cancer Society and LUNGevity Foundation.